Abstract
The in vitro effects of goats milk from different sources (Jonica, Saanen, and Priska breeds plus a commercial preparation) on healthy human peripheral blood mononuclear cells (PBMCs) were evaluated in terms of nitric oxide (NO) and cytokine release. According to the incubation time (24 h or 48 h) used all milks could induce release of NO from monocytes. In this context, however, in the presence of a commercial milk preparation inhibition of lypopolysaccharide (LPS)-induce NO generation was evident. Also polymorphonuclear cells stimulated with the various milks released detectable amounts of NO. In the case of Priska milk inhibition of LPS-mediated NO generation was observed. Despite a broad array of cytokines tested [Interleukin (IL)-4, IL-5, IL-6, IL-10, IL-12, IL-13, IL-17, Tumor Necrosis Factor (TNF)-α, Transforming Growth Factor-β and Granulocyte Colony Stimulating Factor] only IL-10, TNF-α, and IL-6 were released by PBMCs upon stimulation with various milks. Taken together, these data indicate that goats milk for its capacity to produce NO may exert a cardioprotective and anti-atherogenic effect in consumers. Moreover, induction of proinflammatory (TNF-α and IL-6) and anti-inflammatory (IL-10) cytokines suggests the ability of this milk to maintain immune homeostasis in the immunocompromised host (e.g., aged people).
Keywords: Interleukins, milk, peripheral blood mononuclear cells, nitric oxide
Current Pharmaceutical Design
Title: Ability of Goat Milk to Modulate Healthy Human Peripheral Blood Lymphomonocyte and Polymorphonuclear Cell Function: In vitro Effects and Clinical Implications
Volume: 16 Issue: 7
Author(s): F. Jirillo, G. Martemucci, A.G. D'Alessandro, M.A. Panaro, A. Cianciulli, M. Superbo, E. Jirillo and T. Magrone
Affiliation:
Keywords: Interleukins, milk, peripheral blood mononuclear cells, nitric oxide
Abstract: The in vitro effects of goats milk from different sources (Jonica, Saanen, and Priska breeds plus a commercial preparation) on healthy human peripheral blood mononuclear cells (PBMCs) were evaluated in terms of nitric oxide (NO) and cytokine release. According to the incubation time (24 h or 48 h) used all milks could induce release of NO from monocytes. In this context, however, in the presence of a commercial milk preparation inhibition of lypopolysaccharide (LPS)-induce NO generation was evident. Also polymorphonuclear cells stimulated with the various milks released detectable amounts of NO. In the case of Priska milk inhibition of LPS-mediated NO generation was observed. Despite a broad array of cytokines tested [Interleukin (IL)-4, IL-5, IL-6, IL-10, IL-12, IL-13, IL-17, Tumor Necrosis Factor (TNF)-α, Transforming Growth Factor-β and Granulocyte Colony Stimulating Factor] only IL-10, TNF-α, and IL-6 were released by PBMCs upon stimulation with various milks. Taken together, these data indicate that goats milk for its capacity to produce NO may exert a cardioprotective and anti-atherogenic effect in consumers. Moreover, induction of proinflammatory (TNF-α and IL-6) and anti-inflammatory (IL-10) cytokines suggests the ability of this milk to maintain immune homeostasis in the immunocompromised host (e.g., aged people).
Export Options
About this article
Cite this article as:
Jirillo F. , Martemucci G., D'Alessandro A.G. , Panaro M.A., Cianciulli A., Superbo M., Jirillo E. and Magrone T., Ability of Goat Milk to Modulate Healthy Human Peripheral Blood Lymphomonocyte and Polymorphonuclear Cell Function: In vitro Effects and Clinical Implications, Current Pharmaceutical Design 2010; 16 (7) . https://dx.doi.org/10.2174/138161210790883534
DOI https://dx.doi.org/10.2174/138161210790883534 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Patent Selections
Recent Patents on Biomarkers Scintigraphic Imaging of Inflammatory Processes
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Basic and Clinical Research Against Advanced Glycation End Products (AGEs): New Compounds to Tackle Cardiovascular Disease and Diabetic Complications
Recent Advances in Cardiovascular Drug Discovery (Discontinued) Flavonoids in Cancer Prevention
Anti-Cancer Agents in Medicinal Chemistry OX40:OX40L Axis: Emerging Targets for Immunotherapy of Human Disease
Current Immunology Reviews (Discontinued) TNF-α in Tuberculosis: A Cytokine with a Split Personality
Inflammation & Allergy - Drug Targets (Discontinued) Vitamin, Mineral, and Drug Absorption Following Bariatric Surgery
Current Drug Metabolism Insight into p95HER2 in Breast Cancer: Molecular Mechanisms and Targeted Therapies
Recent Patents on DNA & Gene Sequences Natural Sesquiterpene Lactones in the Prevention and Treatment of Inflammatory Disorders and cancer: A Systematic Study of this Emerging Therapeutic Approach based on Chemical and Pharmacological Aspect
Letters in Drug Design & Discovery Targeted Therapies in the Treatment of Advanced Renal Cell Carcinoma
Recent Patents on Anti-Cancer Drug Discovery Advancement in Obesity Management: Leptin and Adiponectin Patents
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Can Untargeted Metabolomics Be Utilized in Drug Discovery/Development?
Current Topics in Medicinal Chemistry Targeting Toll-like Receptors in Autoimmunity
Current Drug Targets Targeting Mammalian Target of Rapamycin: Prospects for the Treatment of Inflammatory Bowel Diseases
Current Medicinal Chemistry Gut Homing Molecule Regulation of the Pathogenesis and Treatment of Inflammatory Bowel Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Patent Annotations
Recent Patents on Inflammation & Allergy Drug Discovery Rationally Designed Multitarget Agents Against Inflammation and Pain
Current Medicinal Chemistry Potential Applications of Bacterial Cellulose in Environmental and Pharmaceutical Sectors
Current Pharmaceutical Design Towards Understanding the Role of Cancer-Associated Inflammation in Chemoresistance
Current Pharmaceutical Design Strategies for Non-Invasive Molecular Imaging of Acute Allograft Rejection by Gamma Scintigraphy and Positron Emission Tomography
Current Radiopharmaceuticals